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Summal'y 
IP-10 is a member of the chemokine family of cytokines and is induced in a variety of cells in 
response to interferon 3' and lipopolysaccharide. The self-aggregation common to many chemokines, 
including IP-10, has hindered the identification of a specific Ipol0 receptor. Using an IPol0 alka- 
line phosphatase fusion protein that fortuitously blocks this self-aggregation, we have identified 
an IP-10 binding site on a variety of cells including endothelial, epithelial, and hematopoietic 
cells. This binding site has a Ka of 25 riM, is inhibited by recombinant murine or human IP-10, 
and is dependent on the presence of cell surface heparan sulfate proteoglycans (HSPG).  This 
conclusion is based on the findings that IP-10 binding to cells is: (a) inhibited by heparin and 
heparan sulfate;  (b) sensitive to a 1 M NaCI wash; (c) eliminated by treatment with heparinase 
and trypsin; and (d) absent on mutant CHO cells that do not express cell surface HSPG. Platelet 
factor 4 (PF4), but not IL-8, monocyte chemoattractant protein-I, RANTES, monocyte inflam- 
matory protein (MIP)-lot,  or MIP-I~/, can compete effectively with IP-10 for binding to the 
cell surface. Furthermore, IP-10 shares with PF4 the ability to inhibit endothelial cell prolifera- 
tion (IC50 =  150 nM). These studies demonstrate specificity in the interaction of chemokines 
and HSPG, and they define IP-10 and PF4 as a distinct subset of chemokines sharing an HSPG- 
binding site and angiostatic properties. 
I 
P-10 was identified as an abundant RNA induced by IFN-3' 
and lipopolysaccharide (2, 3) and encodes a 10-kD secreted 
protein.  It is a member of the -C-X-C- (or or) chemokine 
family of secreted 8-10-kD proteins and is 31% identical to 
platelet factor 4 (PF4) 1 and 26% identical to Ib8, two other 
members of the -C-X-C- chemokine family. IP-10 expression 
is induced in a variety of tissues in inflammatory conditions, 
such as psoriasis  (4),  fixed drug eruptions  (5),  cutaneous 
delayed-type hypersensitivity reactions (6), experimental glo- 
merulonephritis (7), and in experimental allergic encephalo- 
myelitis (8). IP-10 also has a potent in vivo antitumor effect 
that is T cell dependent (9). IP-10 may be a chemoattractant 
for T cells and monocytes, and it may induce T  cells to ad- 
here to activated endothelial cells (10), although these latter 
in vitro findings remain controversial (11). 
Chemokine receptors are known to be promiscuous, binding 
more than one chemokine, and various leukocytes are known 
1  Abbreviations used in this paper: AP, alkaline phosphatase; bFGF, basic 
fibroblast growth factor; DHFR, dihydrofolate  reductase; FBS, fetal  bo- 
vine serum; h, human; HS, heparan sulfate; HSPG, HS proteoglycan; 
HUVEC, human umbilical cord vein endothelial  cell; m, murine; MCP, 
monocyte  chemoattractant  protein; MIP, monocyte  inflammatory  protein; 
PF4, platelet factor 4; SEAP, secreted  AP. 
to have more than one chemokine receptor, making interpre- 
tation of binding data difficult. The recent molecular cloning 
of several chemokine receptors, including monocyte inflam- 
matory protein (MIP)-lot/RANTES, monocyte chemoattrac- 
tant protein (MCP)-I, and the erythrocyte chemokine recep- 
tors,  as well as the demonstration of binding and signaling 
in heterologous cells, has been important in clarifying receptor- 
ligand interactions (12). All the chemokine receptors cloned 
to date are members of the G protein-coupled seven trans- 
membrane spanner family, and, with the exception of the 
promiscuous erythrocyte chemokine receptor (which is the 
Duffy blood group antigen), they induce transient rises in 
intracellular  calcium  upon  activation.  To  date,  however, 
a signaling receptor has not been identified for several chemo- 
kines, including IP-10 and the first chemokine to be identified, 
PF4. PF4 has been shown to bind to cell surface heparan sul- 
fate proteoglycans (HSPG) (13,  14) and may, in fact, exert 
its biological effects of tumor inhibition and angiostasis by 
displacing growth factors such as basic fibroblast growth factor 
(bFGF) (15) and TGF-/~ (16), which use cell surface HSPG 
as part of their receptor complexes. 
To identify IP-10's cellular targets and to help clarify its 
physiological function and mechanism of signal transduction, 
we have set out to identify and characterize its specific cell 
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like many other chemokines, aggregates in solution and on 
the  plasma  membrane,  hampering  attempts  at  obtaining 
equilibrium-binding constants using radiolabeled IP-10.  To 
overcome this problem, we have constructed an IP-10-alka- 
line phosphatase  (IP-10-AP) fusion gene that,  when intro- 
duced into mammalian cells, results in the secretion of a nonago 
gregating monomeric fusion protein that can bind to cells 
via its NH2-terminal  IP-10 epitope and then be enzymati- 
cally assayed via its COOH-terminal alkaline phosphatase tail. 
Using this fusion protein, we have found a specific, non-cal- 
cium fluxing, cell surface heparan sulfate (HS) binding site 
for IP-10 on a variety of cells. This binding site is shared with 
PF4,  and we now find that IP-10 also shares with PF4 the 
ability to inhibit  endothelial  cell proliferation. 
Materials and Methods 
Materials.  Heparin was obtained from Hepar Inc. (Franklin, 
OH). Heparan sulfate, chondroitin sulfate A, chondroitin sulfate 
B, heparinase I, and heparinase III (heparitinase I) were obtained 
from Sigma Immunochemicals (St.  Louis,  MO;  catologue Nos. 
H-7641, C-0914, C-2431, H-2519 and H-889, respectively). Human 
rlL-8  was  purchased  from Genzyme Corp.  (Cambridge,  MA); 
human rMIP-lc~, MIP-I~,  RANTES, and MCP-1 were initially 
supplied by Dr. Tom Schall (Genentech, South San Francisco, CA) 
and then subsequently purchased from PeproTech, Inc. (Rocky Hill, 
NJ). Human rPF4 was supplied by Repligen (Cambridge, MA). 
Cell Lines and Cell Culture.  Cell lines were obtained from Amer- 
ican Type Culture Collection (Rockville, MD) with the following 
exceptions:  the  SV-40-transformed murine endothelial cell line 
SVEC (17) was obtained from Dr. Kathryn A. O'Connell (Johns 
Hopkins University, Baltimore, MD) and CHO K1, 803, and 677 
were obtained  from Dr. J.  Esko  (University of Alabama,  Bir- 
mingham, AL). The 803 and 677 cell lines are mutant CHO cells, 
defective in HS synthesis, derived from CHO-K1 parental wild- 
type CHO cells (18). Mutant  803 produces 5-10%  residual  HS 
and about one-half the normal level of chondroitin sulfate. Mutant 
677 does not synthesize HS and overexpresses chondroitin sulfate 
by a factor of 3 so that the total amount of sulfated glycosaminogly- 
can is comparable in 677 and wild-type cells. Mutant  677 lacks 
both N-acetylglucosaminyltransferase and glucuronosyltransferase, 
enzymes required for the polymerization of HS chains (19). Human 
peripheral blood leukocytes and leukocytes nonadherent to nylon 
wool were kindly provided by Dr. Robert Finberg (Dana Farber 
Cancer Institute, Boston, MA). Leukocytes were grown in RPMI 
supplemented with 10% fetal bovine serum (FBS) (Sigma), fibrob- 
last  lines  and SVEC cells were grown in DMEM  (Sigma)  sup- 
plemented with 10% enriched calf serum (Sigma), human umbil- 
ical cord vein endothelial cells (HUVECs) (Clonetics, San Diego, 
CA) were grown in M199 (GIBCO BRL, Gaithersburg, MD) sup- 
plemented with  10%  heat-inactivated FBS  and  5  ng/ml bFGF 
(R & D Systems, Inc., Minneapolis, MN), and wild-type and mu- 
tant CHO cells were grown in Ham's F12 medium (GIBCO BILL) 
supplemented with 10% FBS. All media were supplemented with 
50 U/ml penicillin, 50 #g/m1 streptomycin, and 2 mM t-glutamine; 
in addition, the murine leukocyte lines were supplemented with 
57 #M 2-ME. All cells were maintained at 37~  and 5% CO2. 
Bone marrow cells were harvested from the femurs of pathogen- 
free FVB female mice as described (20) and were maintained either 
in 30% L cell-conditioned medium (source of macrophage colony- 
stimulating factor) and 20% FBS for 2 wk to obtain macrophages 
or 50% WEHI-conditioned medium (source of ID3) for 4 wk to 
obtain mast cells (21). 
Pro~'n Ex~ession and Purification.  Recombinant murine IP-10 (2) 
beginning with the putative mature NH2-terminal Ile (nucleotide 
129) and terminating with the COOH-terminal Pro (nucleotide 
359) and human riP-10 (1) beginning with the mature NH2-termi- 
nal Val (nucleotide 132) and terminating with the COOH-terminal 
Pro (nucleotide 363) were engineered by PCR using the murine 
IP-10 (9) and human IP-10 (1) cDNAs as templates,  respectively, 
into the Barn H1 site of the Qiaexpress  vectors pQE12 and pQE8 
(QIAGEN Inc., Chatsworth, CA) and then transformed into the 
Escherichia coli strain M15.  Expression of IP-10 in pQE12 results 
in a fusion protein containing a (His)6 carboxy-terminal tag and 
expression of IP-10 in pQE8 results in a fusion protein containing 
an amino-terminal six histidine tag. In addition, both vectors also 
result in the addition of Met-Arg-Gly-Ser at the amino terminus 
of the His-tagged proteins, riP-10 was purified by sedimentation 
of inclusion bodies through sucrose, solubilization of the inclusion 
bodies in 4 M guanidine HC1, af~nity chromatography on nickel 
agarose (QIAGEN Inc.), and reverse phase HPLC (Waters Chro- 
matography, Milford, MA). HPLC was performed on a C18 Vydac 
(Hespirio, CA) column (2.2 cm I.D.) at a flow rate of 9.5 ml/min, 
monitoring absorbance at 214 and 277 nm. The column was eluted 
with a linear gradient of increasing acetonitrile concentration. The 
specific conditions were: 5% B for 5 min, 5-50% B over 30 min, 
50-90% B over 15 min, and then 95% B for 15 min with B being 
80% acetonitrile/0.054% TFA acid and the remaining percentage 
being A, which was 0.06% TFA in water. For the studies reported 
in this paper, after HPLC purification and lyophilization, IP-10 was 
dissolved in PBS; however,  it was subsequently found that IP-10 
was more soluble and aggregated less when it was dissolved in water. 
The concentration of purified protein was determined with a Brad- 
ford assay (Bio-Rad Laboratories,  Melville, NY) with BSA and bo- 
vine y-globulin as standards. 
Two eukaryotic expression systems were used to express human 
IP-10: a murine Moloney virus long terminal repeat-based vector 
(9) transfected into J558L plasmacytoma cells and a dihydrofolate 
reductase (DHFR) resistance plasmid, pJOD-S (22), transfected into 
the double DHFR deletion mutant CHO line DG44 (23).  The 
complete human IP-10 coding sequence, the 5' Pstl-Clal fragment 
(nucleotides 1-384) of the human IP-10 cDNA,  was blunt-end 
ligated into the EcoRI site ofa MoLTR-SV40 I/pA-expression vector 
that had been treated with the Klenow fragment of DNA poly- 
merase. Transfection ofJ558L plasmacytoma cells was performed 
by electroporation (24). 20 #g of linearized MoLTR-IP10 expres- 
sion vector plasmid DNA and 1/~g of linearized neomycin resis- 
tance plasmid pSV7Neo were used to transfect 5  x  10  ~ cells. After 
48 h in RPMI medium, cells were centrifuged and resuspended 
in selective media containing 0.8 mg/ml of G418 (as calculated for 
100% antibiotic activity; Geneticin; GIBCO BRL) and plated in 
serial dilutions into 96 well plates  to clone by limiting dilution. 
G418-resistant  cells from single wells were expanded and a second 
round of cloning by limiting dilution in selective media was per- 
formed to ensure clonality. One clone, 4B6, expressing '~20 ng/ml 
IP-10, as determined by a solid-phase  ELISA (9),  was chosen as 
the source of secreted IP-10. To try to obtain higher levels of IP-10 
secretion, a second eukaryotic expression  system using a one-step 
methotrexate selection  was used.  For this purpose, the complete 
coding sequence of human IP-10 was engineered into the SalI site 
of the mammalian expression vector pJOD-S by blunt-end liga- 
tion. 200/~g of the expression plasmid pJOD-IPl0 linearized with 
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troporated into the DHFR-deficient CHO clone DG44 as described 
(22). A one-step amplification with 0.5 #M methotrexate (Sigma) 
was  performed  in  10%  dialyzed  FBS  and  MEM-cr  lacking 
ribonudeotides  and  deoxyribonucleotides  (GIBCO  BRL).  In- 
dividual clones were picked after 14 d of selection by ring isolation 
and expanded. 25 clones were initially assayed for the level of IP-10 
expression by Northern blot and immunoblot using rabbit anti- 
IPl0 antiserum. Clone 12D3G4 expressed ~10 ng/ml of IP-10 (as 
determined subsequently by ELISA) and was chosen as the source 
of secreted IP-10. Conditioned medium from transfected cells grown 
in serum free medium (Nutridoma from Boehringer Mannheim 
for J558L; CHO-S-SFM from GIBCO BILL for CHO cells) was 
collected and passed over a heparin Sepharose column (Pharmacia 
Fine Chemicals, Piscataway,  NJ). After step elutions with a NaC1 
gradient, an aliquot of each fraction was analyzed by SDS-PAGE 
and Western blotting using an affinity-purified rabbit anti-IP-10 
antibody (25). The fraction containing IP-10 immunoreactive ma- 
terial was then purified by reverse-phase HPLC using the acetoni- 
trile gradient previously described. HPLC fractions were then ana- 
lyzed by SDS-PAGE on a 12.5% SDS-polyacrylamide gel using a 
Tris/Tricine buffer system (26) that has good resolution in the low 
molecular weight region, followed by either Coomassie staining 
or Western blotting using rabbit anti-human IP-10 antisera (see 
below). IP-10 purified from J558L and CHO had the same appear- 
ance on SDS-PAGE. 
Antibody Preparation.  For immunizations, both human and mu- 
fine IP-10 were purified from E. coli as described above, except that 
the eluate from the nickel-agarose chromatography column was 
separated on a denaturing SDS-polyacrylamide gel. The region of 
the gel containing  IP-10 was cut out  and emulsified with com- 
plete Freund's adjuvant for the primary immunization and with 
incomplete Freund's adjuvant for subsequent immunizations. Three 
8-wk-old female New Zealand white rabbits were injected subcutane- 
ously with ~200 mg per rabbit of the carboxy-terminal tagged 
protein (IP-10-(His)6). The rabbits were boosted twice, at 1-mo in- 
tervals, with 100 mg of the amino-terminal tagged protein ((His)6- 
IP-10) per rabbit to ensure the generation of antibodies  recognizing 
the native NHz and COOH termini of IP-10. 10 d after the second 
boost, the three rabbits were bled, and the serum was isolated and 
a portion was pooled for affinity purification. Affinity purification 
of antiserums was performed as described (25) using the His-tagged 
riP-10  coupled to CNBr-activated Sepharose  beads  (Pharmacia). 
Radiolabeling rlP-lO.  IP-10 purified from E. coli was labeled with 
the 12sI Bolton and Hunter reagent (Amersham) according to the 
manufacturers  instructions  and  unincorporated  12SI-Bolton and 
Hunter reagent was removed on a NAP-5 column  (Pharmacia). 
The Bolton and Hunter reagent was chosen to radiolabel Ipol0 be- 
cause IP-10 contains no tyrosines amenable to chemical modification 
with mI. Radiolabeled IP-10 (specific activity =  154 ng/#Ci) was 
also supplied by Dr. Garth Brown (NEN/DuPont)  who radiola- 
beled PeproTech IP-10 by the Bolton and Hunter method and then 
purified it by reverse phase HPLC. 
Production of lP-IO-AP Fusion Protein.  Human and murine IP-10 
was expressed as a soluble fusion protein with the secreted form 
of placental alkaline phosphatase (AP) by engineering the human 
and mouse cDNAs for IP-10 into the APtag vector (27). This was 
accomplished by PCR using the 5' primer CGCAAGCTTCGG- 
GAGACATTCCTCAATTGC and  the  3' primer CGCGGATC- 
CAGGAGATCTTTTAGACATTTC for human IP-10,  as well as 
the 5' primer ACAGATCTAAGCGCTTCATCCACCGCTGA and 
the 3' primer GCGAGATCTAGGAGCCCTTTTAGACCTTTT  for 
murine IP-10  and the human and mouse IP-10 cDNA clones as 
templates, respectively. After digestion of the human PCK product 
with HindlII and BamHI and the mouse PCK product with BgllI, 
they were ligated into the HindlII/BgllI and BgllI site of the APtag 
vector, respectively.  This resulted in fusion proteins that contained 
the authentic signal sequences  and entire mature proteins fused in 
flame with secreted AP (SEAP) via the four-amino acid linker Gly- 
Ser-Ser-Gly for human IP-10 and Arg-Ser-Ser-Gly for murine IP-10. 
The IP-10-APtag phsmids linearized with Sail were co-transfected 
with the selectable  marker pSV7neo into NIH-3T3 cells by the 
calcium phosphate method. After selection with 0.4 rag/m1 G418 
(GIBCO BRL) in 96-well plates (6.4 mm per well), "~100 individual 
clones were screened for secreted alkaline phosphatase activity. This 
assay was performed by heating 50 #1 of the supernatant at 65~ 
for 10 min to inactivate background cellular phosphatase activity 
and then measuring the A40s on a V~, kinetic microplate reader 
(Molecular Devices, Menlo Park, CA) after incubating with 1 M 
diethanolamine, pH 9.8, 0.5 mM MgC12, 10 mM L-homoarginine 
(a phosphatase inhibitor),  and  12 mM p-nitrophenyl phosphate 
(Sigma), all prepared as a 2 x  stock solution (SEAP buffer). The 
highest expressing NIH-3T3 clones,  18.G5 for murine and 17.G2 
for human IP-10-AP produced 1,000  mOD/ml per min and 800 
mOD/ml per rain, respectively,  were used for the experiments de- 
scribed in this paper. A control NIH-3T3 clone expressing unfused 
SEAP was produced by transfecting with plasmid pBC12/CMV/ 
SEAP. Other control fusion proteins such as, human and murine 
IL-4-AP and kit-AP were kindly provided by Drs. B. Morrison (Dana 
Farber Cancer Institute, Boston, MA) and J. Flannagan (Harvard 
Medical School, Boston,  MA),  respectively. 
To determine the specific activity of the proteins, the concentra- 
tion of IP-10-AP in the supernatant was estimated by quantitative 
immunoprecipitation  (see  below)  followed by SDS-PAGE  with 
Coomassie blue staining and comparing the intensity of Coomassie 
staining compared to BSA standard dilution. To determine the effi- 
ciency of immunoprecipitation, the amounts of AP activity in the 
initial sample and the remaining AP activity next two sequential 
immunoprecipitations were determined and used as a correction 
factor to calculate for <100% efficiency of immunoprecipitation. 
The resulting estimate for the specific activity of murine IP-10-AP 
was 30 mOD/min per ng, which is similar to the specific activity 
determined for Ib4-AP (100 mOD/min  per ng;  reference 38). 
Immunoprecipitation and Immunoblotting.  1 ml of conditioned 
media from the NIH-3T3 clone 18.G5 secreting mIP-10-AP was 
collected, centrifuged at 1,000 g, and protease inhibitors  (Boehringer 
Mannheim Biochemicals) were added to the supernatant at the fol- 
lowing concentrations: leupeptin (0.3 ng/ml), aprotinin (10 ng/ml), 
PMSF (20 ng/ml), and pepstatin (0.8 ng/ml). The supernatant was 
then centrifuged at 10,000 g for 30 min at 4~  and then precleared 
for 4 h at 4~  with 50 #1 of a 1:1 slurry of protein A-Sepharose 
(PAS) (Pharmacia). The PAS was then centrifuged at 10,000 g in 
eppendorf tubes, and 50 #1 of a 1:1 slurry of a mAb to placental 
AP (catalogue No. A-018-02; Medix Biotech, Foster City, CA) cou- 
pled to CNBr-activated Sepharose (Pharmacia) was added to the 
supernatant for 2 h at 4~  The beads were recovered by centrifu- 
gation at 10,000 g for 10 rain and a second immunoprecipitation 
was performed by adding another 50 #1 of a 1:1 slurry of mAb- 
Sepharose beads and incubating for another 2 h at 4~  The im- 
munoprecipitates were then washed 3 x  with 1 ml of KIPA buffer 
(0.15 M  NaC1, 1% NP-40, 0.1% SDS,  0.5%  deoxycholate, 0.05 
M Tris, pH 8.0) and then boiled for 3 min in 50 #1 of sample buffer 
containing 0.3  M  2-ME, 4% SDS.  20 #1 was then analyzed on 
a  Laemmli  10%  SDS-polyacrylamide  gel  and  the  intensity  of 
Coomassie staining was compared to a dilution  series of BSA. 
For immunoblotting, gds were transferred to Immobilon-P mem- 
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(Owl  Scientific,  Woburn,  MA)  blocked  with  3%  nonfat  dry 
milk/3% goat serum (Sigma)/PBS and incubated with a 1:10,000 
dilution of affinity-purified rabbit anti-IP-10 antiserum for 2 h at 
room temperature. The membranes were then washed 2 x  10 min 
each with PBS/.1% Tween 20,  lx  10 min with RIPA buffer, and 
then 2x  10 min each with PBS/.1% Tween 20, and then incubated 
with a 1:20,000 dilution of peroxidase-conjugated goat anti-rabbit 
IgG (catalogue No. 111-035-003; Jackson ImmunoResearch Labora- 
tories, West Grove, PA) for I h at room temperature in 3% nonfat 
milk and 3% goat serum in PBS. The membrane was then washed 
as described above and developed using an ECL chemiluminescence 
kit (Amersham). 
Binding Assays.  For nonadherent cells,  107 cells were washed 
lx  with ice-cold binding buffer (HBSS/10 mM Hepes/0.1% BSA) 
and resuspended in the indicated concentration of IP-10-AP and 
competitors in a total of 100 #1 ice-cold binding buffer. Binding 
was carried out for 2 h on ice with occasional mixing. Cells were 
washed 5 x  with ice-cold binding buffer by repeated centrifuga- 
tion at 4~  Cell-bound AP activity was determined by lysing cells 
in  100/~1 of 10 mM "Iris, pH 8.0/1%  Triton X-100, heating at 
65~  for 10 min to inactivate cellular AP, and then centrifuging 
at 14,000 g for 10 min. 50/zl of the soluble lysate was then mixed 
with 50/~1 2 x  SEAP buffer in a 96-well plate at room tempera- 
ture,  and the colormetric product was assayed in a kinetic plate 
reader at A40s. For adherent cells with higher numbers of binding 
sites, binding was determined in six-well cluster plates. Cells were 
washed 2 x  with ice-cold binding buffer and incubated with the 
indicated concentration of IP-10-AP and competitor in a total of 
500/~1  of ice-cold binding buffer for 2 h  in the cold room on a 
rocker platform. Cells were washed 6 x  with binding buffer, lysed 
with 100/~1 of 10 mM Tris, pH 8.0/1% Triton X-100, scraped into 
an Eppendorf tube, and then assayed as described above. Nonspecific 
binding was determined in one of two ways. For the calculation 
of the equilibrium constant, nonspecific binding was determined 
by adding  10 mM riP-10 at each concentration of IP-10-AP and 
performing the binding experiments in parallel exactly as described 
above. Specific binding was determined by subtracting background 
from total binding.  Specifc binding data was analyzed with the 
binding equation B  =  (Bin= x  F)/(Kd  + F), where B is bound 
ligand and F is free ligand (28),  using the program KaleidaGraph 
(Synergy Software, Reading,  PA) on a Macintosh computer. For 
other experiments, nonspecific binding was determined by adding 
equal amounts of nonfusion SEAP or cross-species  IL-4-AP (hlL-4 
does not bind to mouse cells and mouse IL-4 does not bind to human 
cells) and performing the binding experiments in parallel  exactly 
as described above. To obtain IP-10- AP at concentrations higher 
than the concentration found in the conditioned medium of trans- 
fected cells, transfected cells were maintained in serum-free DMEM 
for 14 d and the conditioned medium was concentrated 100-fold 
by ultrafiltration (Amicon Corp., Beverly, MA). '2sI-IP-lO binding 
to cells was performed essentially as described above for IP-IO-AP 
binding,  except the cell pellet with bound IP-IO was counted in 
a gamma counter. 
Heparinase and Trypsin Treatment.  For adherent calls,  106 cells 
were washed lx  with serum-free DMEM and then incubated in 
500/~1 serum-free DMEM at 37~  and 5% CO2 for 1 h with ei- 
ther 2.5 U/m1 heparinase I or 0.2 U/m1 heparinase III (heparitinase) 
(29). For nonadherent ceils, 107 cells were washed lx  with serum- 
free RPMI and resuspended in 100 #1 RPMI plus the concentrations 
of Heparinase I and III indicated above. After enzyme treatment, 
adherent cells were washed 4 x  with 5 ml binding buffer and nonad- 
herent cells were washed 2 x  with 10 ml binding buffer, then assayed 
for IP-10-AP binding as described above.  Confluent monolayers 
(,~107 cells) of adherent cells were washed lx  with calcium- and 
magnesium-free HBSS and  incubated for 5 min 37~  and 5% 
COz  with  0.25%  trypsin/0.02%  EDTA  (JRH  Biosciences, 
Lexena, KA). After enzyme treatment, the cells were washed with 
10  ml DMEM/10%  FBS  and  10  ml binding  buffer,  and  then 
resuspended in  100/zl binding buffer and assayed for IP-10-AP 
binding  as described above. 
Endothelial CellProliferation  Assay.  HUVECs were routinely used 
between passages 17 and 30. Cellular proliferation was determined 
by incorporation of [3H]thymidine into DNA as previously de- 
scribed (30). Briefly, rhlP-10 and rhPF4 were added to HUVECs 
plated in 96 well plates (6  x  103 cells per well) grown in M199/ 
10% FBS/5 ng/ml FBS. 3 d later,  the amount of [3H]thymidine 
incorporated into DNA per well was determined. Samples were 
tested in triplicate. 
Calcium Flux.  THP-1, A20, and EL4 cells were resuspended 
at 2  x  106 cells per ml in RPMI 1640 containing 2% FBS and 
5/~g/ml Fura 2-am (Molecular Probes Inc., Eugene, OR) (diluted 
from a 1 mg/ml stock in dimethyl sulfoxide).  THP-1 cells were 
incubated for 1 h, and A20 and EL4 cells were incubated for 30 
min at 37~  and were then washed three times in 145 mM NaC1, 
4 mM KC1,  1 mM NaH2PO4, 0.8 mM MgCI2, 1.8 mM CaC12, 
10 mM glucose, and 25 mM Hepes (pH 7.4). Cells were resuspended 
at 106 cells per ml in this buffer, and 2-ml samples were loaded 
into a fluorimeter (LS-5B;  Perkin-Elmer Cetus Corp., Norwalk, 
CT) for measurements ofintracellular calcium. Excitation and emis- 
sion wavelengths were 399 and 510 nm, respectively.  Maximum 
calcium-Fura 2 fluorescence was measured after treating loaded cells 
with 1% Triton X-100 and minimum calcium-Fura 2 fluorescence 
was measured after the addition of 100 mM Tris, pH 8.0 and 100 
mM EGTA. 
Results 
Purification of rlP-lO Expressed in E. coli.  Human and mu- 
rine IP-10 were generated as recombinant proteins tagged at 
either the NH2 or COOH  terminus with (His)6. Both NH2 
terminally  and  COOH  terminally  His-tagged  IP-10 were 
generated  to  minimize  the  possibility  that  the  (His)6  tag 
could interfere with receptor binding and biological activity 
or mask a potentially important epitope when raising anti- 
bodies to riP-10.  IP-10 was purified by sedimentation of in- 
clusion bodies (which contained the insoluble recombinant 
protein) through sucrose, solubilization of the inclusion bodies 
in 4  M  guanidine  HC1,  affinity chromatography on nickel 
agarose, and then reverse-phase HPLC eluting with an acetoni- 
trile  gradient  (Fig.  1 A).  Although  there  appears to be  a 
shoulder on the IP-10 peak, SDS-PAGE analysis of fractions 
across this  peak revealed a  homogenous protein.  II>-10 was 
then radiolabeled with  12SI-Bolton and Hunter reagent and 
subjected  to reducing  SDS-PAGE  (Fig.  1 B).  Under  these 
purification conditions, IP-10 appears to aggregate into mul- 
timers.  At  the exposure shown in Fig.  1 B  monomers and 
dimers are evident;  but  at longer exposures and on heavily 
loaded Coomassie-stained gels, higher  order multimers  are 
seen. These multimers are reactive with affinity-purified rabbit 
anti-IP-10 antiserum and are unaffected by reduction and ir- 
reversible alkylation of sulfhydryls  (data not  shown).  This 
aggregation is not the result of the (His)6 tag,  since a non- 
222  I1>-10 Shares a Cellular Binding Site with PF4 and Is Angiostatic Figure  1.  Expression  and purification  of E. coli riP-10. (A) Reverse-phase  HPLC  purification  of riP-10. Histidine-tagged  hiP-10 expressed in E. coil 
was purified  on nickel  affinity  chromatography  and the bound fraction  was applied to a C-18 Vydac  column  and eluted with a gradient of acetonitrile. 
Curved arrow indicates  position of IP-10 on A214 chromatogram.  The first  peak that is off scale is the urea-loading  buffer. (/3) 12.5% SDS-PAGE (Tris/Tri- 
cine) analysis  of Bolton and Hunter 125I-labeled  rhlP-10. (Lane I ) 12SI-labeled  PeproTech human IP-10 (NEN/Du Pont). (Lane  2) The (His)6-tagged 
hlPol0 shown in A. The slower migration  of the IP-10 monomer and oligomers seen in lane 2 compared with lane 1 is presumably  caused by the 
additional six histidines. Molecular  mass markers are indicated to the right of the gel in kilodaltons. 
fusion version of IP-10 (Du Pont/NEN) behaved similarily 
(Fig.  1 B). 
Purification of rlP-lO Secreted  from J558L Plasmacytoma and 
CHO Cells.  Since IP-10 purified from E.  coli aggregated, 
it was of interest to determine if IP-10 purified from eukary- 
otic cells and not subjected to denaturation and renaturation 
would also aggregate. The complete IP-10 cDNA was there- 
fore engineered into the two expression vectors, MoLTR/SV- 
40 I/pA and pJOD-S, and then stably transfected into J558L 
and CHO cells, respectively.  IP-10 was secreted  from both 
stably transfected lines in similar amounts as  judged by a solid- 
phase ELISA and had similar electrophoretic mobility profiles. 
IP-10  was  purified from  conditioned medium by heparin 
Sepharose affinity chromatography followed by reverse-phase 
HPI.C (Fig. 2). This purification demonstrates that IP-10 binds 
to heparin Sepharose  at physiological NaC1 concentrations 
and is eluted beteween 0.5 M  and L0 M  NaC1 (Fig.  2 A). 
The 1-M eluate from the heparin Sepharose column was sub- 
jected to reverse-phase HPLC analysis (Fig. 2 B). Fractions 
eluted with a gradient of increasing acetonitrile were ana- 
lyzed by SDS-PAGE  and immunoblotted with an affinity- 
purified anti-IP-10  antiserum (Fig 2 C). The fraction contain- 
ing immunoreactive IP-10 is indicated on the chromatogram 
in Fig. 2 B by an arrow.  IP-10 secreted and purified from eu- 
karyotic cells also aggregates under these purification and dec- 
trophoresis conditions (Fig. 2, A  and C). The aggregation 
of the E. coli synthesized material is therefore not unique to 
the bacterial product and reflects a property of the molecule. 
Furthermore, the E. coli- and J558Loproduced IP-10 have the 
same reverse phase HPLC elution profile (compare position 
of curved arrow on chromatogram in Fig. 1 A with position 
of curved arrow on chromatogram in Fig. 2 B), suggesting 
they have similar properties. 
IP-IO-AP Binding to Cells is Specific, Saturable, and Competed 
by PF4.  Since radiolabeled riP-10  produced in E.  coli ag- 
gregated in solution and on cell surfaces (see below), it was 
impossible to identify a specific saturable IP-10 binding site. 
To overcome this problem, IP-10 was expressed as an AP fu- 
sion gene that, when introduced into mammalian cells, resulted 
in the secretion of a nonaggregating monomeric fusion pro- 
tein that bound to cells via its NH2-terminal IP-10 epitope 
and enzymatically assayed via its COOH-terminal AP tail 
(Fig. 3). Both murine (m) and human (h)Ipol0 were engineered 
into the APtag vector and initially used for binding studies. 
However, since no species specificity was apparent and the 
murine fusion protein had less nonspecific binding, all data 
presented in this report used the murine IP-10-AP AP fusion 
protein (IP-10-AP). The specific activity of the IP-10-AP was 
estimated by determining the amount of AP activity in I ml 
of conditioned medium and then estimating the amount of 
223  Luster  et al. Figure  2.  Purification of recombinant IP-10 secreted  from J558L cells. 
Heparin Sepharose af~nity chromatography of serum-free conditioned 
medium collected  from  J558L cells  transfected  with a human IP-10  cDNA 
expression construct analyzed by reverse phase HPLC. (A,  top panel) 
Coomassie stained 12.5% SDS-PAGE  (Tris/Tricine)  of  fractions  eluted step- 
wise from a heparin Sepharose  column with the indicated  concentrations 
of NaC1. (A, bottom  panel) Immunoblot of equivalent gel stained with 
af~nity-purified  rabbit anti-hiP-10 antibody. L, cell lysate; P, precolumn; 
F, column flow through. Lanes  1-3 represent  sequential  fractions  collected 
at the NaC1  concentration indicated  above  the number. (B) Reverse-phase 
HPLC profile of 1 M NaC1 eluate from heparin Sepharose  column. (C) 
12.5% SDS-PAGE  of HPLC fractions shown in B, (Top  panel) Coomassie- 
stained gel. (Bottom  panel) Immunoblot using affinity-purified  rabbit anti- 
IP-10 antiserum. Dotted arrow indicates direction of increasing acetoni- 
trile concentration. Solid arrows indicate position of monomeric IP-10. 
Molecular mass markers are indicated to the left of the gel in kilodaltons. 
Curved arrow in B indicates IP-10 peak as determined by immunoblot 
of HPLC factions shown in C. 
IP-10-AP protein by quantitative immunoprecipitation using 
an mAb  specific for AP. 
Using  IP-10-AP,  we have been able to demonstrate that 
IP-10 binds  specifically to a variety of cells and binds with 
a Ka of 25 nM on A20 B cells (Fig. 4 A). IP-10-AP binding 
was 100% inhibited by 10 #M recombinant murine or human 
IP-10 on A20 B cells and EL4 T  cells; however, when other 
chemokines were tested for their ability to compete for Ipo 
10-AP binding  to A20 B  cells and  EL4 T  cells,  only hPF4 
could inhibit  100%  of mlP-10-AP  binding.  At  ",~100-fold 
molar  excess,  hlL-8,  hMIP-lol,  hMIP-1B,  hRANTES  had 
virtually no effect, but hMCP-1 did partially compete (data 
not shown). Since hMCP-1 partially competed in one experi- 
ment, we performed a dose-inhibition experiment comparing 
mlP-10, hPF4, and hMCP-1 (Fig. 4 B). In this experiment, 
while hPF4, mlP-10, and heparin (see below) could compete 
for IP-10-AP binding  to cells in a dose-dependent manner, 
hMCP-1  had no effect on mlP-10-AP,  binding even at  100 
#g/ml ("~10 #M or *600-fold molar excess). The discrepancy 
between the two experiments could relate to a change in the 
source of hMCP-1  (initially from Genentech and then from 
PeproTech). Of note, the inhibition curve using E. coli pro- 
duced  IP-10 was  shifted to the right  probably because the 
effective molarity of the IP-10 solution was lower than ex- 
pected because of the  aggregation  of riP-10. 
IP-IO-AP Inhibits  the Aggregation of  lP-lO on Cells.  To test 
the hypothesis that the AP tail of the IP-10-AP fusion pro- 
tein was inhibiting the aggregation of IP-10 on the cell sur- 
224  IP-10 Shares a Cellular Binding Site with PF4 and Is Angiostatic Figure 3.  IP-10-AP.  (.4) Schematic of mammalian expression vector 
APtag. This plasmid carries high level  transcription control elements from 
the Moloney murine leukemia virus LTR, 3' splice, and polyadenylation 
signals from the rat insulin gene and a domain of the human placental 
alkaline  phosphatase  gene. Inserting the murine IP-10  cDNA into the cloning 
site results in the creation of an IP-10-AP fusion gene. (/3) Conditioned 
face, A20 B cells were incubated with tz~I-hlP-10 in the pres- 
ence of increasing concentrations of either unlabeled hiP-10 
or IP-10-AP. As can be seen in Fig. 5,  the addition of cold 
competitor  hiP-10  resulted in  more  125I-hlP-10  binding  to 
cells, whereas the addition of IPol0-AP was able to compete 
with t2SI-hlP-10 binding to intact cells. Thus,  the increased 
binding of 12sI-IP-10  to  cells in  the  presence of increasing 
cold nonfusion IP-10 is likely a consequence of aggregation 
of IP-10 on  the  cell surface. 
IP-IO Binding Does Not Induce a Cakium Flux in A20, EL4, 
and THP-I Cells.  Since most chemokines have been reported 
to induce a transient calcium flux in cells that have specific 
cell surface receptors, we tested the ability of I1)-10 to flux 
calcium in A20 B  cells and EL4 T  cells. Neither  the A20 
medium from NIH-3T3 cells transfected with above  vector was immuno- 
precipitated using a mAb to AP, subjected to 10% SDS-PAGE, and then 
immunoblotted  with rabbit antimurine  IP-10 antibody. 
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Figure 4.  IP-10-AP  binding is specific, saturable and 
competed by PF4 and heparin. (.4) IP-10-AP binding to 
A20 B cells. 107 A20 B cells were incubated with in- 
creasing concentrations of mlP-10-AP. Specific  binding 
= total binding  -  nonspecific  at each point. Nonspecific 
binding was determined by performing the binding assay 
at each concentration of  IP-10-AP  in the presence  of  excess 
(10 #M) unlabeled murine  riP-10. (B)  Concentration- 
dependent inhibition.  107  A20 B cells were incubated 
with 15 nM murine IP-10-AP in presence  of the indicated 
concentrations of unlabeled recombinant chemokines or 
heparin for 2 h at 4~  Cells were then washed and bound 
IP-10-AP was assayed.  Data is presented as the percentage 
of binding  =  (binding in presence of competitor minus 
nonspecific  binding/binding in the absence  of competitor 
-  nonspecific  binding)  x  100. Nonspecific  binding was 
determined by the amount of human IL-4-AP  or secreted 
AP bound to murine A20 cells and was usually <1% of 
the total binding. 
225  Luster et al. 2500 
E  2000 
=  1500 
0 
o  1000 
w 
50~ 
Figure  5. 
co:o:::; 
-- a--  IP-10-AP 
I  oJr  "r 
D1  o.01  o11  i  10  10o  looo 
Concentration  (nM) Cold Competitor 
IP-10-AP inhibits aggregation of Ipol0 on cell surfaces. 2  x 
106 A20 cells were incubated for 2 h  at 4~  with  10 nM  n5I-hlP-10 
(NEN/Du Pont) in the presence of the indicated concentrations of unla- 
beled 11)-10 or IP-10-AP fusion protein. The cells were then washed 5 x 
with binding buffer and assayed for cell-bound 12Sl-hlP-10. 
or EL4 cell lines fluxed calcium in response to recombinant 
E.  coli- or J558L-  produced  mlP-10  or  to mlP-10-AP,  even 
though  the A20 B  cell line fluxed calcium following cross- 
linking  of  its  membrane  bound  IgG  with  an  anti-IgG2b 
mAb  (data  not  shown).  We  also  tested  the  responsiveness 
of the THP-1 cell line to IP-10 stimulation.  THP-1 cells are 
a monocytic cell line that can specifically bind  IP-10 (albeit 
at lower levels than the A20 or EL4 cell lines) and have been 
reported  to  flux  calcium  to  various  chemokines.  The  data 
shown  in  Fig.  6  A  demonstrates  that  the binding  of mlP- 
10-AP  to THP-1 cells can be inhibited  by excess human  or 
mouse IP-10, but not by hMIP-lot or hMIP-1/3.  HL60 cells 
do not bind mlP-10-AP and were included as a negative con- 
trol.  As  can be seen  in  Fig.  6  B,  THpol  cells loaded  with 
Fura-2 were able to demonstrate a transient calcium flux upon 
stimulation  with  hMCP-1,  hRANTES,  and hMIP-lot,  but 
were unable  to flux calcium upon  addition  of hlpol0.  Fur- 
thermore,  hiP-10  was unable  to  desensitize  THP-1  cells  to 
subsequent hMCP-1 or hRANTES stimulation.  In contrast, 
hMIP-lot desensitized THP-1 cells to subsequent hRANTES 
or  hMCP-1  stimulation.  In  addition,  heparin  and  heparan 
sulfate (100 ng/ml), molecules that augment IL-8 signal trans- 
duction (31), did not enable I1)-10 to signal (data not shown). 
Glycosaminoglycan Inhibition of  lP-lO Binding.  Heparin and 
heparan sulfate were able to completely block IP-10-AP binding 
to cells in a concentration-dependent  manner (Fig. 7). Chon- 
droitin  sulfate B  (dermatan  sulfate)  was also able to inhibit 
IP-10-AP binding  to A20 B  cells,  but  at higher  concentra- 
tions than heparin or heparan sulfate. In contrast, chondroitin 
sulfate A had no effect on IP-10-AP binding, even at I mg/ml, 
whereas  heparin  and  HS  completely  inhibited  IP-10-AP 
binding at 10 #g/ml.  In fact, heparin's inhibition  curve was 
almost superimposable on PF4's inhibition curve (Fig. 4 B). 
Cellular Distribution of lP-10 Binding  Sites.  Table  1  sum- 
marizes the results of multiple experiments showing the cel- 
lular distribution  and approximate density of IP-10 binding 
sites on a number of different cell types.  IP-10 binding sites 
are present in higher numbers on adherent cells like endothelial 
Figure  6.  11)-10  binds to the chemokine responsive  THP-1 cell line, but 
does not induce a detectable  intraceUular  calcium  flux. (A) Specific  binding. 
107 THP-1 or HL60 cells were incubated for 2 h at 4~  with 15 nM IP- 
10-AP in the presence of various competitors: none, hiP-10 and mlP10, 
MIP-lc~ and MIP-13 (THP-1 cells only). The cells were then washed 5 x 
with HBSS-binding  buffer and assayed  for cell-bound AP activity. (B) Cal- 
cium flux. THP-1 cells  were loaded with Fura-2 and assayed  by spectophoto- 
metric methods at 37~  with continuous stirring. Addition of indicated 
recombinant human chemokine to THP-1 cells is illustrated by arrow. All 
chemokines were added to a final concentration of 10 nM, except for the 
second addition of 11)-10, which was added to 100 nM. 
cells,  fibroblasts,  and  epithelial  cells.  Furthermore,  IFN-7 
pretreatment  of BM macrophages,  U937,  THP-1,  or HL60 
cells did not  induce  IP-10 binding  sites on  these cells (data 
not shown).  In addition,  the activation of thymocytes with 
anti-CD3 mAb (2Cll) for 24 h had a minimal (approximately 
twofold)  enhancement  of IP-10 binding  sites.  As seen with 
other  cells,  however,  Ipol0 binding  to  resting  or  activated 
thymocytes was inhibited by heparin or HS, and binding was 
completely lost if the cells were treated with heparinase (data 
not shown).  Unfractionated human peripheral blood leuko- 
cytes had trace IP-10 binding  that was lost if the cells were 
passed over nylon wool, indicating  that binding sites are lo- 
cated on macrophages or B cells and not on peripheral blood 
T  cells. 
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Figure  7.  Glycosaminoglycan  inhibition  of IP-10-AP binding  to A20 
cells. 107 A20 cells were incubated  with 15 nM mlP-10-AP in the pres- 
ence of the indicated  concentrations  of  heparin (H), heparin sulfate  (HS), 
chondroitin sulfate B (CSB), and chondroitin sulfate  A (CSA) for 2 h 
on ice. Cells were then washed and bound IP-10-AP was assayed. 
IP-IO Binding to Cells is Dependent on Surface HSPG.  Since 
heparin and heparan sulfate inhibited IP-10-AP  binding to 
cells, and IP-10-AP binding sites were found in higher numbers 
on adherent cell lines,  we tested whether this binding site 
is salt and heparinase sensitive.  Fig. 8 A  demonstrates that 
the IP-10-AP binding site on fibroblasts is also competed for 
by heparin and excess IP-10, and that it is sensitive to heparinase 
treatment and an 1-M NaC1 wash. Heparinase I treatment 
of BALB/c-3T3 cells enzymatically removed "~75% of the 
IP-10-AP  binding sites while having no effect  on kit-AP 
binding to the kit ligand. Heparinase III also removed "~84% 
of the IP-10-AP  binding sites on NIH-3T3 cells (data not 
shown). This is also true for the binding site on A20 B cells, 
where Heparinase I and III removed 100 and 75%, respec- 
tively (data not shown). In addition, after binding and washing 
in HBSS, a l-rain wash in HBSS adjusted to 1 M NaC1 re- 
moved all of the IP-10-AP from BALB/c-3T3 and only 50% 
of kit-AP from these same cells. 
The IP-10 binding site is also sensitive to trypsin digestion 
on three cell lines tested, NIH-3T3, BALB/c-3T3, and SVEC, 
a mouse endothelial cell line (Fig.  8 B). A further demon- 
stration that IP-10 binding is dependent on cell surface heparan 
sulfate comes from studies using two CHO mutants that lack 
HSPG because  of mutations in enzymes that are necessary 
for glycosaminoglycan biosynthesis. As can be seen in Fig. 
9, IP-10-AP  binds to wild-type parental CHO line K1, but 
does not bind to either of the mutant lines,  677  and 803. 
Furthermore, soluble heparan sulfate does not restore binding 
to the mutants, but in fact, inhibits the binding of IP-10-AP 
to the wild-type CHO cells in a concentration-dependent 
fashion. 
IP-IO Inhibits HUVEC Proliferation.  Since PF4 was able 
to compete with IP-10 for binding to several cell lines tested, 
including A20 B cells and NIH 3T3 cells, and since PF4 was 
known to inhibit bFGF-induced proliferation of endothelial 
cells, the effect of IPol0 on the growth of  HUVECs was tested 
(Fig.  10 A). Like PF4, which has an IC50 of 100-200  nM, 
IP-10 half maximally inhibits HUVEC proliferation at 150 
nM (1.5/~g/ml). However, it required at least fivefold more 
IP-10 to reach 100% inhibition compared to PF4, which again 
may reflect a propensity of IP-10 to aggregate at high con- 
centrations, decreasing its effective molarity. The inhibition 
by submaximal concentrations of PF4 and IP-10 are additive 
(data not shown). As is the case for PF4, increasing concen- 
trations of exogenous heparin reverses the inhibitory effects 
Table  1.  Expression of lP-lO Binding Sites by Different Cell Types 
Approximate No. 
Cell Type  Cell line  of sites/cell  Nondetectable 
Endothelial  SVEC  400,000 
Fibroblast  NIH/3T3  330,000 
Balbc/3T3  165,000 
Epithelial  CHO K1  1,650  CHO 833 and 677 
Monocytic  THP-1  1,320  U937, J774, 
RAW 264.7 
B lymphocytic  A20, AJ9  660  MIC, BJAB 
T lymphocytic  EL4, LBRM  330  JURKAT, HSB, MBP 
Leukocytes  Unfractionated  Trace  Nylon passed 
BM culture  Macrophages  825  Mast cells 
Thymocytes  Resting  165 
Nondetectable indicates there was no significant  binding over background binding. Background  binding was determined  using either cross-species 
IL4-AP or secreted AP binding to cells. Number of sites per cell was determined  by using the specific  activity  estimated  for IP-10-AP (30 mOD/min 
per ng). 
227  Luster  et al. Figure  9.  IP-10-AP binds  to wild-type CHO (K1) cells but does not 
bind to the heparan  sulfate-deficient mutant CHO cells (677 and 803). 
106 cells were incubated for 2 h at 4~  with 15 nM IP-10-AP in the pres- 
ence of 10 #M unlabeled mlP-10 or the indicated concentration  of heparin. 
The monolayers were then washed 5x with HBSS-binding buffer and the 
amount of bound IP-10-AP was determined. 
Figure  8.  The IP-10 binding site is heparinase, salt, and trypsin  sensi- 
tive. (A) 106 BALB/c-3T3  cells were incubated  with either 15 nM mlP- 
10-AP or an equivalent amount of kit-AP in the presence of no compet- 
itor (None), 1/zM mlP-10, or 100/~g/ml heparin for 2 h at 4~  Samples 
labeled H'ase 1 were treated for 30 rain at 37~  with heparinase 1 in serum- 
free medium and then washed with complete medium before the binding 
assay. After binding, all cells were washed  5x  in HBSS; the samples la- 
beled 1 M NaCI received an additional  l-rain wash with HBSS adjusted 
to 1 M NaC1. The amount of bound AP activity was then enzymatically 
determined.  (/3) 107 cells were trypsinized  with 0.25%  Trypsin/1  mM 
EDTA for 5 rain at room temperature  after which they were incubated 
with 15 nM mlP-10-AP for 2 h at 4~  washed 5x  with HBSS binding 
buffer, and assayed for bound AP activity. Binding was determined  in par- 
allel on an equivalent number of untrypsinized cells. SVEC, an SV-40  trans- 
formed murine endothelial  cell line. 
of IP-10 upon proliferation, just as it does to the inhibitory 
effects of PF4 (Fig. 10 B). A comparison of the binding affinity 
of each, IP-10 and PF4,  for soluble  heparin shows  the Ka 
values to be equivalent at 10 -7 M (Daly, T., personal com- 
munication). Neutralizing antibodies to PF4 that block PF4's 
inhibition  of HUVEC proliferation had no effect on IP-10's 
inhibition  of proliferation (data not shown). PF4 and IP-10 
do not induce apoptosis in HUVECs; they cause a growth 
arrest. When PF4 or IP-10 are washed away (by the addition 
of heparin 5 U/ml) from HUVECs that have been growth 
arrested by these chemokines and fresh media containing bFGF 
is added back to the cultures, cellular proliferation resumes 
(data not shown). 
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Figure  10.  IP-10  inhibits  endothelial  proliferation,  an effect that is antagonized  by heparin.  (tt) HUVECs were plated in triplicate in a 96-well plate 
in the presence of the indicated  concentration  of hiP-10 or hPF4,  5 ng/ml bFGF,  and  10%  FBS. The amount of [3H]thymidine  incorporated  into 
each well was determined on day 3.  (B) 6  x  103 HUVECs were plated with the bFGF-containing  media  and with the indicated  concentration  of 
heparin alone or with heparin  plus 5/zg/ml IP-10 or 10 pg/ml of PF4 for 3 d, and the amount of [3H]thymidine  during that period was determined. 
228  IP-10 Shares a Cellular  Binding Site with PF4 and  Is Angiostatic Discussion 
One of the major problems in studying the properties of 
IP-10 was that, like other chemokines (32,  33),  IP-10 self- 
aggregates at physiological pH and tonicity. This aggrega- 
tion  interfered with  our  ability  to  identify a  specifc  and 
saturable Ipol0 cellular binding site. To overcome this problem, 
we generated an IP-10-AP fusion protein that retained its ability 
to bind to cells, but that did not aggregate in physiological 
buffers. Using this fusion protein, we demonstrated that IP-10 
binds to a cell surface HSPG receptor with a Kd of 25 nM. 
The conclusion that this receptor is a HSPG rests on the 
observations that cellular IPol0 binding is inhibited by heparin 
and HS, eliminated by treatment with heparinase and trypsin, 
and absent on mutant CHO cells that do not express cell 
surface HSPG. 
The binding of IP-10 to its HSPG receptor is a specific 
interaction. Only PF4 and certain glycosaminoglycans com- 
pete for IP-10 binding to cells. Heparin and heparan sulfate 
are equipotent in competing for IP-10 binding sites, while 
chondroitin sulfate B is >--100 fold less potent and chondroitin 
sulfate A is unable to compete for these sites. Further, PF4 
is as potent as heparin in competing with IP-10 binding to 
cells, while IL-8, R.ANTES, MIP-lo~,  MIP-I~, and MCP-1 
have virtually no inhibitory effect on IP-10. Although IL-8 
binds heparin and is almost as homologous to IP-10 as PF4 
(26 vs 31%), it does not effectively compete for IP-10's cel- 
lular HSPG sites. Interestingly, human and murine IP-10 com- 
peted with murine IP-10-AP and with human IP-10-AP for 
cellular binding (data not shown), suggesting that there is 
no binding specificity between these species. It is also striking 
that Ipol0 is less potent on a weight basis  than either PF4 
or heparin in competing with IP-10-AP binding. This ob- 
servation is consistent with the formation of Ipol0 aggregates, 
decreasing its effective molar concentration. Aggregation may 
also explain the fourfold lower Ka found for IP-10 binding 
to soluble heparin as compared with IP-IO-AP binding to 
cells.  Since the monomeric fusion protein  IP-10  binds  to 
cells, aggregation of IP-10 is not required for binding to its 
HSPG receptor. Our approach of using a fusion protein to 
inhibit self-aggregation might be generally applicable to other 
chemokines. 
We also demonstrated that like PF4, IP-10 inhibits bFGF- 
induced proliferation of endothelial cells. Moreover, heparin 
antagonizes this inhibition, suggesting that the antiprolifer- 
ative effect of IP-10 is mediated through this same HSPG 
receptor. The specific HSPG site that PF4 and IP-10 share 
may be a physiologically relevant site at which these mole- 
cules modulate the action of other cytokines that use HSPG 
as part of their receptor complex. For example, PF4 can in- 
hibit both bFGF (15) and TGF-~ (16) binding to cells. In- 
deed, this may be the mechanism whereby PF4 and IP-10 
exert their antiproliferative  effects and may explain the growth 
regulating properties that the chemokines have on many di- 
verse cell types (34-37). 
Our results do not exclude the possibility that there is an- 
other receptor for IP-10. Nonetheless, we were unable to de- 
tect an IP-10 binding site on human peripheral lymphocytes, 
even though it has been reported that IP-10 is a chemotactic 
for peripheral blood T cells (10). Furthermore, we have been 
unable to detect a calcium flux in cells that specifically bind 
IP-10.  It nonetheless remains quite possible that by fusing 
IP-10 to AP, we have destroyed the ability of IP-10 to interact 
with its signaling receptor while preserving its ability to in- 
teract with a specific HSPG-binding site. Although this is 
possible,  other,  albeit  nonchemokine alkaline phosphatase 
fusion proteins (e.g., human and mouse IL-4 [38],  kit [27], 
and fibroblast growth factor receptor (FGFR)  [39])  retain 
their ability to interact with their specific cell-surface receptor 
or ligands. 
One other role for heparin and cell surface HSPG is in 
enhancing signaling of cytokines to their signaling receptor 
chains. For example, FGF signaling through its tyrosine ki- 
nase receptor, FGFK1,  requires either soluble or cell sur- 
face-bound HSPG (40).  The HSPG receptor betaglycan is 
also involved in TGF-/3 signaling. Betaglycan presents TGF-/3 
directly to the serine/threonine kinase subunit of the signaling 
receptor, forming a high affinity ternary complex (41). It has 
been demonstrated that heparin and heparan sulfate enhance 
neutrophil responses to IL-8 (31) and augment the ability of 
MIP-1/3 (42) to induce T  cell adhesion. The mechanism of 
this enhancement has not been examined and, indeed, it is 
not known whether cell surface HSPG or soluble heparin 
is  actually required for chemokines to bind to  and signal 
through their seven transmembrane spanner receptors. This 
question could be experimentally approached by comparing 
the ligand binding and signaling properties of wild-type and 
HSPG-deficient CHO cells that have been transfected with 
cloned chemokine receptors. 
Chemokines are known to bind to heparin, and it has been 
proposed from studies that found immunoreactive MIP-1B 
in the distribution of endothelial cells that they bind cell sur- 
face HSPG (42). HSPG on cell surfaces may capture chemo- 
kines from the fluid phase,  thereby immobilizing and estab- 
lishing a gradient of chemokine that can then be presented 
to  rolling leukocytes and perhaps  serve as  a  substrate for 
chemotaxis or hapotaxis (43). The specificity of the chemo- 
kine-HSPG interaction may play a role in regulating leuko- 
cyte homing and the recruitment of leukocytes to sites of 
inflammation.  This  could  be  accomplished  through  the 
differential expression of specific HSPG on endothelial cells 
in different tissues, or through the induction of specific HSPG 
by specific inflammatory stimuli. The expression of HSPGs 
with  affinity for only a  subset  of chemokines in  a given 
microenvironment would then allow only those chemokines 
captured in that microenvironment to be presented to rolling 
leukocytes. Thus,  those chemokines with  affinity for the 
regionally expressed or induced HSPG would be able to more 
effectively deliver a signal to circulating leukocytes. This hy- 
pothesis has not been explored for the chemokines, but the 
concept of HSPG-ligand specificity dictating a biological re- 
sponse has been established for the FGF family (44). 
Constitutive expression of IP-10 is seen in the thymus and 
in the spleen, and high levels of expression are seen in various 
229  Luster  et al. inflammatory conditions. It is therefore useful to consider 
the possibility that IP-10 plays a role in regulating immune 
and inflammatory responses by modulating the action of other 
cytokines that use HSPG as part of their receptor complex. 
Both IP-10 and PF4 have been demonstrated to inhibit the 
growth of tumors (9, 45), possibly through immunologic, 
inflammatory, and/or angiostatic mechanisms. PF4 is in fact 
now in clinical trials as an antitumor agent. In preliminary 
experiments, we have shown that injection of IP-10 into a 
tumor transplant site has an antitumor effect (Luster, A. D., 
and P. Leder,  unpublished observation). In considering the 
pharmacological delivery of IP-10 or PF4 to tumors, one should 
bear in mind HSPG receptors may be expressed on the tumor 
cells themselves, as well as on the endothelial and inflamma- 
tory cells that may be a part of the effector mechanism in 
the antitumor response. 
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